Celsius aims to cool down inflammation with new investors and more pharma deals

Broad Institute spinout Celsius Therapeutics is turning up the heat on the financing front as it looks to ice the symptoms of inflammatory bowel disease.

The Cambridge, MA biotech has added $83 million in new financing — a mixture of a Series A extension and Series B funds — to...

Click to view original post